Covid 19 Research using Clinical Trials (Home Page)
Report for D004194: Disease NIH
(Synonyms: Disea, Diseas, Disease)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug417 | Impact of Event Scale-Revised Wiki | 0.50 |
| drug216 | Connor-Davidson Resilience Scale 10 items (CD-RISC 10) Wiki | 0.50 |
| drug256 | Depression, Anxiety and Stress Scale Wiki | 0.50 |
| drug136 | Brief Psychiatric Rating Scale Wiki | 0.50 |
| drug300 | Exposure to the SARS-CoV-2 and its consequences Wiki | 0.50 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000066553 | Problem Behavior NIH | 0.71 |
| D001523 | Mental Disorders NIH | 0.61 |
| D009461 | Neurologic Manifestations NIH | 0.50 |
| D007153 | Immunologic Deficiency Syndromes NIH | 0.35 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 4 clinical trials
Clinical Trials
1 The Impact of the Covid-19 Pandemic on the Mental Health of Workers in Health Services: The Covid-19 HEalth caRe wOrkErS (HEROES) Study
Since December 2019 the world has been shaken with an enormous global threat: the Covid-19 pandemic. This new kind of coronavirus is generating an unprecedented impact both on the general population and on the healthcare systems in most countries. Health services are trying to expand their capacity to respond to the pandemic, taking actions such as increasing the number of beds; acquiring necessary equipment to provide intensive therapy (ventilators), and calling retired health professionals and health students so they can assist the overwhelmed health care workforce. Unfortunately, these organizational changes at health facilities, along with the fears and concerns of becoming ill with the virus or infecting their families, put an enormous emotional burden on workers in health services which may lead to negative outcomes on mental health in this population. Recent cross-sectional studies in China indicate that health service workers exposed to people with Covid-19 reported higher rates of depressive and anxious symptoms. This negative impact on mental health among health workers in China has also been informally reported in other countries where the Covid-19 pandemic has been devastating in its effects (such as Spain and Italy), as well as in countries where the pandemic is becoming a growing public health problem. This is particularly relevant in regions with fewer resources (Latin America, North Africa), where there are limited means and the response from the health system is usually insufficient. Moreover, it is necessary to study these negative effects longitudinally considering that some effects will appear over time (post-traumatic stress). Accordingly, this prospective (0, 3, 6 and 12 months), multisite cohort study aims to describe, examine, and evaluate the impact of the Covid-19 pandemic on mental health and social factors among workers at health services from Latin America and the Caribbean, Europe and neighboring countries, the Middle East and North Africa, as well as Sub-Saharan Africa and Asia. Additionally, a team from the United States of America will also participate in this collaborative effort providing expertise on psychiatric epidemiology and supporting coordination across countries.
NCT04352634 Covid-19 Mental Health Disorder Stress Disorder Anxiety Depression SARS-CoV-2 Other: Exposure to the SARS-CoV-2 and its consequences MeSH:Disease Mental Disorders
Primary Outcomes
Description: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: 12 monthsSecondary Outcomes
Description: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: BaselineDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: 3 monthsDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: 6 monthsDescription: Ad hoc survey on experiences, fears, and concerns about Covid-19
Measure: Experiences, fears and concerns about the Covid-19 Time: 12 monthsDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: BaselineDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: 3 monthsDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: 6 monthsDescription: Ad hoc survey on Covid-19 training and resource prioritization
Measure: Training and resource prioritization Time: 12 monthsDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: BaselineDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: 3 monthsDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: 6 monthsDescription: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)
Measure: Suicide ideation (presence) Time: 12 monthsDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: BaselineDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: 3 monthsDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: 6 monthsDescription: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.
Measure: Suicide ideation (frequency) Time: 12 monthsDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: BaselineDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: 3 monthsDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: 6 monthsDescription: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms
Measure: Acute stress symptoms Time: 12 monthsDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: BaselineDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: 3 monthsDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: 6 monthsDescription: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support
Measure: Psycho/social support and network Time: 12 monthsDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: BaselineDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: 3 monthsDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: 6 monthsDescription: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.
Measure: Resilience Time: 12 monthsDescription: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: BaselineDescription: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: 3 monthsDescription: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries
Measure: Anxiety and depressive symptoms Time: 6 months2 Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.
NCT04354818 HIV-1-infection Cancer Primary Immune Deficiency Disorder Immunosuppression Disorders COVID-19 MeSH:Immunologic Deficiency Syndromes Disease
HPO:Immunodeficiency
Primary Outcomes
Measure: percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died Time: Day 28
Secondary Outcomes
Measure: percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died Time: 3 months
3 PSYCHIatric Disorders and Covid-19 (PSYCHIC) : Observatory of the Psychiatric, Somatic and Pharmacological Impacts of the COVID-19 Pandemic on Patients Hospitalized for Psychiatric Disorders and Suspected to be Infected by COVID-19
Primary Outcomes
Measure: percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died Time: Day 28Secondary Outcomes
Measure: percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died Time: 3 monthsGiven the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with psychiatric disorders and suspected of infection, hospitalized in a specific unit, at the psychiatric, somatic and pharmacological level.
NCT04358042 Psychiatric Disorder Covid19 Other: Brief Psychiatric Rating Scale Other: Depression, Anxiety and Stress Scale Other: Impact of Event Scale-Revised Other: Connor-Davidson Resilience Scale 10 items (CD-RISC 10) MeSH:Disease Mental Disorders Problem Behavior
HPO:Behavioral abnormality
Primary Outcomes
Description: total severity score from the Impact of Event Scale-Revised (IES-R)
Measure: impact of the COVID-19 pandemic on psychiatric symptomatology Time: through study completion, an average of 2 year
4 Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations
Primary Outcomes
Description: total severity score from the Impact of Event Scale-Revised (IES-R)
Measure: impact of the COVID-19 pandemic on psychiatric symptomatology Time: through study completion, an average of 2 yearCovid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.
NCT04362930 Neurologic Manifestations Psychiatric Disorders COVID-19 MeSH:Neurologic Manifestations Disease Mental Disorders Problem Behavior
HPO:Behavioral abnormality
Primary Outcomes
Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19
Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 Time: 12 months
Secondary Outcomes
Description: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases
Measure: Progression of pre-existing neurological or psychiatric pathologies Time: 12 months
HPO Nodes
Primary Outcomes
Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19
Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 Time: 12 monthsSecondary Outcomes
Description: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases
Measure: Progression of pre-existing neurological or psychiatric pathologies Time: 12 months